Hailey Liew
Family · Dayton, TNNPI 1871952739
Payments from drug & device makers
Across 149 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$881
- AbbVie$385
- Otsuka America Pharmaceutical, Inc.$280
- Lilly USA, LLC$242
- Lundbeck LLC$139
- Xeris Pharmaceuticals, Inc.$130
- plus $715 from 17 others
What the payments were for
- Food & beverage$2,772100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $881 |
| AbbVie | 24 | $385 |
| Otsuka America Pharmaceutical, Inc. | 13 | $280 |
| Lilly USA, LLC | 16 | $242 |
| Lundbeck LLC | 6 | $139 |
| Xeris Pharmaceuticals, Inc. | 7 | $130 |
| GSK | 6 | $105 |
| Amgen | 4 | $75 |
| Pfizer | 4 | $71 |
| Abbott | 3 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Novartis | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Neurelis, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Exact Sciences | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $14 |
How this compares
$2,772 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 78 | $94,259 |
| EliquisApixaban | 65 | $64,068 |
| OzempicSemaglutide | 33 | $36,269 |
| JanuviaSitagliptin Phosphate | 20 | $18,976 |
| LinzessLinaclotide | 15 | $16,875 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,652 |
| FarxigaDapagliflozin Propanediol | 11 | $12,788 |
| JardianceEmpagliflozin | 13 | $10,195 |
| Atrovent HfaIpratropium Bromide | 20 | $8,864 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,305 |
| Omeprazole | 223 | $2,779 |
| Novolin NInsulin Nph Human Isophane | 17 | $2,377 |
| Valsartan | 19 | $1,742 |
| Tamsulosin Hcl | 110 | $1,651 |
| Levothyroxine Sodium | 215 | $1,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $242 | $94,25978 claims |
| PfizerEliquis | $71 | $64,06865 claims |
| Novo NordiskOzempic | $881 | $36,26933 claims |
| AbbVieLinzess | $385 | $16,87515 claims |
| GSKTrelegy Ellipta | $105 | $13,65211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.
Other family in Dayton
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.